HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ChromaDex To Offer Lower-Dose Tru Niagen At Lower Price In US Walmart Stores

Nicotinamide Riboside Supplement Firm Trims 2020 Net Loss By $12.2M

Executive Summary

ChromaDex expects to expand target market for Tru Niagen while also expanding sales through stocking product at US stores of world’s largest retailer. It also will expand the range of package sizes and prices for its supplement as the product it provides Walmart will be at a lower dose than what it offers for sale online.

You may also be interested in...



Attention Shoppers And Investors: ChromaDex Makes Tru Niagen Available At Walmart

Tru Niagen products available at 3,800 US Walmart stores include a lower dose, 100 mg, that ChromaDex didn't previously market. Launch sparks heavy trading driving up firm's share price.

Swisse Pens Deal To Use ChromaDex’ Niagen In Supplements

Australian-heritage supplements brand Swisse has secured the rights to use ChromaDex' patented Niagen ingredient - marketed to help consumers "age better" - in a new product range.

ChromaDex Hits Consumer Brand Marketing Sweet Spot With Former Nestle Executive In Charge

Tru Niagen supplement firm names Fadi Karam CMO a little more than a month after it announced a distribution deal to put its nicotinamide riboside supplement on shelves at US Walmart stores.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151104

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel